Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Amarin Stock Is Crushing It Today

TheMotleyFool

0 0

Why Amarin Stock Is Crushing It TodayPhoto, wide shot, wide-angle lens, Cleaning service, Midday, harsh overhead sunlight, directional sunlightt, photo by Marc Adamus: https://img.theapi.app/temp/66ee0081-ae60-418d-bd6e-b521f7433841.png

Shares of Amarin (NASDAQ: AMRN) were soaring 22.4% higher as of 11:44 a.m. EST on Tuesday. This big jump came after notes were released in advance of a U.S. Food and Drug Administration (FDA) advisory committee review that pointed to an increased likelihood that the drugmaker could win an expanded indication for Vascepa in reducing cardiovascular risk.

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee is scheduled to meet to review the expanded indication for Vascepa on Thursday. Notes from FDA staff related to the committee's review were released today.

Image source: Getty Images.

Source Fool.com

Like: 0

AMRN

Share